We are live on
!
Find out more
BC
Blackcrane Capital Portfolio holdings
AUM
$16.3M
1-Year Est. Return
19.53%
This Fund
S&P 500
This Quarter
Est. Return
+50.63%
1 Year Est. Return
-19.53%
3 Year Est. Return
+40.04%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$88.4M
AUM Growth
-$21M
(-19%)
Cap. Flow
-$57.8M
Cap. Flow
% of AUM
-65.41%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
8
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMDX
Insight Molecular Diagnostics
IMDX
|
+$7.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
WIX.com
WIX
|
+$19M |
| 2 |
Microsoft
MSFT
|
+$12.3M |
| 3 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
+$11.1M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$7.72M |
| 5 |
Visa
V
|
+$5.32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.34% |
| 2 | Technology | 30.66% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Avita Medical
RCEL
$153M
| $28.1M | 31.84% |
921,663
-111,605
| -11% | -$3.41M |
|
|
2
WIX.com
WIX
$2.21B
| $16M | 18.08% |
62,379
-107,295
| -63% | -$19M |
|
|
AXNX
3
DELISTED
Axonics, Inc. Common Stock
AXNX
| $15M | 17.01% |
428,359
-321,980
| -43% | -$11.1M |
|
|
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $8.98M | 10.16% |
122,865
-145,003
| -54% | -$7.72M |
|
5
Nice
NICE
$5.91B
| $8.26M | 9.35% |
43,657
-23,194
| -35% | -$4.06M |
|
|
IMDX
6
Insight Molecular Diagnostics
IMDX
$152M
| $5.7M | 6.44% |
+149,128
| New | +$7.7M |
|
|
PROF
7
Profound Medical
PROF
$246M
| $2.97M | 3.36% |
175,301
-47,246
| -21% | -$596K |
|
|
8
Microsoft
MSFT
$2.98T
| $2.86M | 3.23% |
14,039
-67,922
| -83% | -$12.3M |
|
9
Takeda Pharmaceutical
TAK
$53.4B
| $461K | 0.52% |
25,723
-109,734
| -81% | -$1.97M |
|
|
10
Visa
V
$694B
| – | – |
-33,024
| Closed | -$5.32M |
|
Similar funds
FQ
AG
SCM
CFG
YEPV
WIA
LSM
FFIM
Blackcrane Capital's Q2 2020 Portfolio in Review
As of Q2 2020, Blackcrane Capital held 10 positions worth $88.4M, down 19% from $109M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Blackcrane Capital withdrew a net $57.8M in Q2 2020, closing 1 position and reducing 8 holdings. Its most notable exit was Visa, an estimated $5.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 59% a quarter earlier, followed by Technology and Financials.
Against the trend, Blackcrane Capital opened a new position in Insight Molecular Diagnostics worth $5.7M.
- Blackcrane Capital's largest Q2 2020 buy was Insight Molecular Diagnostics: 149,128 shares worth $5.7M.
- Blackcrane Capital's biggest Q2 2020 reduction was WIX.com, cutting an estimated $19M.
- Blackcrane Capital fully exited Visa in Q2 2020, selling an estimated $5.32M.
- Blackcrane Capital's ten largest holdings make up 100% of its $88.4M portfolio in Q2 2020.
- Blackcrane Capital opened 1 new position and closed 1 in Q2 2020.
- Blackcrane Capital's portfolio value fell 19% quarter-over-quarter to $88.4M.
Based on Blackcrane Capital's 13F filing for Q2 2020, filed 14 Aug 2020.